合作客户/
拜耳公司 |
同济大学 |
联合大学 |
美国保洁 |
美国强生 |
瑞士罗氏 |
相关新闻Info
推荐新闻Info
-
> 聚氧乙烯链长度调控非离子Gemini表面活性剂的表面张力、接触角(四)
> 聚氧乙烯链长度调控非离子Gemini表面活性剂的表面张力、接触角(三)
> 聚氧乙烯链长度调控非离子Gemini表面活性剂的表面张力、接触角(二)
> 聚氧乙烯链长度调控非离子Gemini表面活性剂的表面张力、接触角(一)
> 饱和腰果酚聚氧乙烯醚磺酸盐动态界面张力测定【实验步骤及结果】
> 最大拉杆法的基本原理、实验步骤、影响因素及其在测定溶液表面张力中的应用
> 麦芽糖醇脂肪酸酯水溶液合成、反应条件及表面张力测定——结果与分析、结论
> 麦芽糖醇脂肪酸酯水溶液合成、反应条件及表面张力测定——摘要、材料与方法
> 多孔陶瓷的造孔方法|发泡剂掺量对多孔陶瓷材料性能的影响
> 棕榈酸二甘醇酰胺无碱条件下降低大庆原油/地层水界面张力——结果和讨论、结论
Delta-8临界胶束浓度对于药物在生物体内的增溶性的重要性研究——结论、致谢!
来源:上海谓载 浏览 1274 次 发布时间:2021-12-21
结论
据我们所知,这是第一个全面的研究,清楚地显示了类药物化合物的内在表面性质对生物相关介质中溶解度增强的影响,而不是在水介质中。这项研究表明,临界胶束浓度(描述化合物在胶束中自缔合的内在能力)比公认的亲脂性更好地预测FaSSIF中的溶解度增强。我们的研究表明,考虑到化合物在胶束中结合的趋势,药物优化策略将潜在地受益,作为增加肠道吸收的一种方式。
作者信息
通讯作者
*电话:+41616881941。传真:+41616882908。电子邮件:鲁本。阿尔瓦雷斯_ sanchez roche.com.
笔记
作者声明没有相互竞争的经济利益。
致谢
作者要感谢比约恩·瓦格纳、维吉尼·米卡列夫、伊莎贝尔·帕里拉和萨宾·皮塔提供的技术援助,以及弗兰兹·舒勒、萨拉·贝利和乔恩·凯尔·博德纳尔对手稿的修订和宝贵意见。
缩写
FaSSIF,禁食状态模拟肠液;FeSSIF,喂食状态模拟肠液;临界胶束浓度;生物制药分类系统;SE,溶解度增强;logd,辛醇/水分配系数;电离常数
参考资料
(1)Amidon,G.L.;Lennernas,H.;Shah,V.P.;Crison,J.R.A theoretical basis for a biopharmaceutic drug classification:the correlation of in vitro drug product dissolution and in vivo bioavailability.Pharm.Res.1995,12(3),413−20.
(2)Tsume,Y.;Mudie,D.M.;Langguth,P.;Amidon,G.E.;Amidon,G.L.The Biopharmaceutics Classification System:Subclasses for in vivo predictive dissolution(IPD)methodology and IVIVC.Eur.J.Pharm.Sci.2014,57,152−63.
(3)Jones,H.M.;Parrott,N.;Ohlenbusch,G.;Lave,T.Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.Clin Pharmacokinetics 2006,45(12),1213−26.
(4)Galia,E.;Nicolaides,E.;Horter,D.;Lobenberg,R.;Reppas,C.;Dressman,J.B.Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.Pharm.Res.1998,15(5),698−705.
(5)Andrieux,K.;Forte,L.;Lesieur,S.;Paternostre,M.;Ollivon,M.;Grabielle-Madelmont,C.Insertion and partition of sodium taurocholate into egg phosphatidylcholine vesicles.Pharm.Res.2004,21(8),1505−16.
(6)Nawroth,T.;Buch,P.;Buch,K.;Langguth,P.;Schweins,R.Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF(mod)estimated by combined timeresolved neutron and dynamic light scattering.Mol.Pharmaceutics 2011,8(6),2162−72.
(7)Mithani,S.D.;Bakatselou,V.;TenHoor,C.N.;Dressman,J.B.Estimation of the increase in solubility of drugs as a function of bile salt concentration.Pharm.Res.1996,13(1),163−7.
(8)Ottaviani,G.;Gosling,D.J.;Patissier,C.;Rodde,S.;Zhou,L.;Faller,B.What is modulating solubility in simulated intestinal fluids?Eur.J.Pharm.Sci.2010,41(3−4),452−7.
(9)Fagerberg,J.H.;Karlsson,E.;Ulander,J.;Hanisch,G.;Bergstrom,C.A.Computational prediction of drug solubility in fasted simulated and aspirated human intestinal fluid.Pharm.Res.2014,32,578−89.
(10)Persson,L.C.;Porter,C.J.;Charman,W.N.;Bergstrom,C.A.Computational prediction of drug solubility in lipid based formulation excipients.Pharm.Res.2013,30(12),3225−37.
(11)Casartelli,A.;Bonato,M.;Cristofori,P.;Crivellente,F.;Dal Negro,G.;Masotto,I.;Mutinelli,C.;Valko,K.;Bonfante,V.A cellbased approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development.Cell Biol.Toxicol 2003,19(3),161−76.
(12)Fischer,H.;Atzpodien,E.A.;Csato,M.;Doessegger,L.;Lenz,B.;Schmitt,G.;Singer,T.In silico assay for assessing phospholipidosis potential of small druglike molecules:training,validation,and refinement using several data sets.J.Med.Chem.2012,55(1),126−39.
(13)Seelig,A.;Gottschlich,R.;Devant,R.M.A method to determine the ability of drugs to diffuse through the blood-brain barrier.Proc.Natl.Acad.Sci.U.S.A.1994,91(1),68−72.
(14)Peresypkin,A.;Kwei,G.;Ellison,M.;Lynn,K.;Zhang,D.;Rhodes,T.;Remenar,J.Supramolecular behavior of the amphiphilic drug(2R)-2-ethylchromane-2-carboxylic acid arginine salt(a novel PPARalpha/gamma dual agonist).Pharm.Res.2005,22(9),1438−44.
(15)Kloefer,B.;van Hoogevest,P.;Moloney,R.;Kuentz,M.;Leigh,M.L.S.;Dressman,J.Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF.Dissolution Technol.2010,17(3),6−13.
(16)Milletti,F.;Storchi,L.;Sforna,G.;Cruciani,G.New and original pKa prediction method using grid molecular interaction fields.J.Chem.Inf.Model.2007,47(6),2172−81.
(17)Mannhold,R.;Poda,G.I.;Ostermann,C.;Tetko,I.V.Calculation of molecular lipophilicity:State-of-the-art and comparison of log P methods on more than 96,000 compounds.J.Pharm.Sci.2009,98(3),861−93.
(18)Pagliara,A.;Carrupt,P.A.;Caron,G.;Gaillard,P.;Testa,B.Lipophilicity profiles of ampholytes.Chem.Rev.1997,97(8),3385−3400.
(19)Vertzoni,M.;Fotaki,N.;Kostewicz,E.;Stippler,E.;Leuner,C.;Nicolaides,E.;Dressman,J.;Reppas,C.Dissolution media simulating the intralumenal composition of the small intestine:physiological issues and practical aspects.J.Pharm.Pharmacol.2004,56(4),453−62.
(20)Kerns,E.H.;Di,L.;Carter,G.T.In vitro solubility assays in drug discovery.Curr.Drug Metab.2008,9(9),879−85.
(21)Lehto,P.;Kortejarvi,H.;Liimatainen,A.;Ojala,K.;Kangas,H.;Hirvonen,J.;Tanninen,V.P.;Peltonen,L.Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs.Eur.J.Pharm.Biopharm.2011,78(3),531−8.
(22)Fagerberg,J.H.;Tsinman,O.;Sun,N.;Tsinman,K.;Avdeef,A.;Bergstrom,C.A.Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.Mol.Pharmaceutics 2010,7(5),1419−30.
(23)Box,K.J.;Comer,J.E.Using measured pKa,LogP and solubility to investigate supersaturation and predict BCS class.Curr.Drug Metab.2008,9(9),869−78.
(24)Avdeef,A.Absorption and Drug Development:Solubility,Permeability,and Charge State,2nd ed.;John Wiley&Sons:Hoboken,NJ,2012;Vol.xli,p 698.